Related by context. All words. (Click for frequent words.) 65 Dr. Christopher Twelves 64 Median survival 60 placebo dexamethasone 57 Psoriasis Area 57 Doxil ® 57 FOLFOX4 56 NATRECOR R 56 achieved ACR# 56 binary restenosis 56 vincristine doxorubicin 56 NSTE ACS 56 VELCADE melphalan 56 paclitaxel eluting stents 55 recurrent GBM 55 radiochemotherapy 55 eribulin 55 oxycodone CR 55 lopinavir r arm 55 FOLFIRI 55 Platinol ® 55 tolvaptan 55 paclitaxel cisplatin 55 FOLFOX4 alone 55 squamous histology 55 angiographic outcomes 55 Severity Index PASI 55 CCyR 54 standard chemotherapy regimen 54 plus prednisone 54 nondiabetic patients 54 Median PFS 54 underwent CABG 54 preoperative chemotherapy 54 pegylated interferon alfa 2b 54 systemic embolism 54 stage IIIb IV 54 Halaven 54 underwent resection 54 receiving highly emetogenic 54 recurrent VTE 54 tenecteplase 54 mitoxantrone plus 54 BEACOPP 54 aminotransferase elevations greater 54 pegylated liposomal doxorubicin 54 Free Survival PFS 53 briakinumab 53 dacarbazine 53 ischemic cardiomyopathy 53 amoxicillin clavulanate 53 MACCE 53 definite stent thrombosis 53 postoperative chemotherapy 53 CYPHER Stent 53 #mg QD [001] 53 mg/m2 dose 53 metastatic GIST 53 TMP SMX 53 non valvular atrial 53 mcg QD 53 sustained virologic response 53 5-FU/LV 53 biochemical relapse 53 PSADT 53 p = NS 53 VcMP 53 uncoated stent 53 Folfox 53 Zometa hazard 53 receiving prophylactic anticoagulation 53 dacarbazine chemotherapy 53 perioperative mortality 53 mitoxantrone 53 receiving VICTRELIS 53 stage IIIB IV 53 progression TTP 52 Hazard Ratio 52 #mg BID [001] 52 chemoradiation 52 ipsilateral stroke 52 mm Stent 52 underwent liver transplantation 52 acute myocardial infarction AMI 52 underwent surgical resection 52 Taxus Stent 52 carboplatin chemotherapy 52 HCV RESPOND 2 52 LVEF 52 undergoing cardiac catheterization 52 achieved PASI 52 plus dexamethasone 52 neoadjuvant chemotherapy 52 chemoradiation therapy 52 Flu Cy 52 dalteparin 52 fluorouracil 52 receiving golimumab 52 interferon ribavirin 52 aspirin heparin 52 doxorubicin cyclophosphamide 52 NATRECOR ® 52 recurrent myocardial infarction 52 BARACLUDE ® 52 diameter stenosis 52 naïve HCV 52 adriamycin 52 PEGINTRON TM 52 undetectable HBV DNA 52 evaluable subjects 52 EXPAREL 52 stage IIIb 52 cyclophosphamide methotrexate 52 XIENCE V demonstrated 52 symptomatic carotid stenosis 52 everolimus eluting stents 52 chemotherapy gemcitabine 52 events MACE 52 adjuvant chemotherapy 52 periprocedural 52 TAXUS Express Stent 51 endoscopic remission 51 chlorambucil 51 fibrillation AF 51 MoxDuo TM IR 51 Operative mortality 51 neurologic progression 51 neoadjuvant treatment 51 biochemical recurrence 51 dose dexamethasone 51 NYHA Class II 51 tirofiban 51 carboplatin paclitaxel 51 Thal Dex 51 REYATAZ r arm 51 pCR 51 epirubicin cyclophosphamide 51 KRAS mutations occur 51 locoregional 51 curative resection 51 locoregional recurrence 51 docetaxel Taxotere 51 prednisone prednisolone 51 advanced epithelial ovarian 51 preintervention 51 pamidronate 51 Median progression 51 ABVD 51 SGRQ 51 MADRS score 51 Myelodysplastic Syndrome MDS 51 reinfarction 51 #mg/day [001] 51 mg kg belimumab 51 8mg/kg 51 adjuvant tamoxifen 51 CYPHER ® Stent 51 FOLPI 51 peginterferon alfa 2a 51 5 Fluorouracil 51 oral allopurinol 51 receiving ISENTRESS 51 Platinol ® cisplatin 51 undergone radical prostatectomy 51 metastatic castration resistant 51 conventional IMRT 51 XELOX 51 #mg/m# [002] 51 deep venous thromboses 51 nadolol 51 FFR guided treatment 51 cytogenetic response 51 ACUITY trial 51 undergoing coronary artery 51 FluCAM arm 51 gemcitabine chemotherapy 51 lipid lowering agents 51 stage IIIB 51 doxorubicin docetaxel 51 comparator arm 51 HDRS 51 adjuvant hormonal therapy 51 levosimendan 51 Rating Scale MADRS 51 cytoreduction 51 % CI #.#-#.# [003] 51 COPD exacerbation 51 peginterferon alpha 2a 51 severe neutropenia 51 cytoreductive surgery 51 OTFC 51 nonmetastatic prostate cancer 51 liposomal doxorubicin 51 perioperatively 51 subcutaneous enoxaparin 51 tobramycin inhalation solution 51 radical prostatectomy RP 51 docetaxel chemotherapy 51 morphometric vertebral fractures 51 workhorse lesions 51 lamivudine monotherapy 51 ALND 51 certolizumab 50 neoadjuvant 50 mg m² 50 CRp 50 HRQoL 50 sUA 50 plus methotrexate 50 dose cytarabine 50 completely resected 50 mitoxantrone chemotherapy 50 metastatic CRC 50 ribavirin RBV 50 patients undergoing CABG 50 insulin detemir 50 asthma exacerbation 50 oral diclofenac 50 GP IIb IIIa inhibitors 50 nicardipine 50 prospectively stratified 50 octreotide LAR 50 median PFS 50 recurrent glioblastoma multiforme 50 oblimersen 50 unstable angina UA 50 metastatic malignant melanoma 50 Gliadel Wafer 50 Peg IFN 50 rituximab refractory 50 ACTEMRA TM 50 valsartan 50 TAXUS VI 50 CYPHER ® 50 INCB# [003] 50 unresectable Stage III 50 nonmetastatic 50 postintervention 50 aspirin clopidogrel 50 postoperative mortality 50 rizatriptan 50 CIMZIA TM certolizumab pegol 50 chemoembolization 50 HBeAg positive patients 50 4mg/kg 50 clinically localized prostate 50 P = .# 50 Pegylated Liposomal Doxorubicin 50 mcg kg REBETOL 50 HBeAg negative patients 50 Navelbine ® 50 CYPHER R Sirolimus eluting 50 tipranavir r 50 low dose Iluvien 50 bypass graft CABG surgery 50 irinotecan cisplatin 50 anthracycline taxane 50 mg simvastatin 50 clodronate 50 placebo p = 50 tumor progression TTP 50 preoperative radiotherapy 50 IV NSCLC 50 FOLFOX 50 hip BMD 50 detectable HCV RNA 50 mcg albinterferon alfa 2b 50 beta blocker therapy 50 peginterferon alfa 2a Pegasys 50 Jevtana 50 coronary interventions 50 primary hypercholesterolemia 50 CLARITY study 50 ARB telmisartan 50 advanced adenomas 50 Myocardial Infarction Study 50 piperacillin tazobactam 50 mRCC 50 virologic failure 50 visceral metastases 50 PSA nadir 50 acute coronary syndromes ACS 50 NEVO ™ 50 stable angina 50 relapsed MM 50 irbesartan 50 generalized edema 50 Events MACE 50 FOLFIRI alone 50 carotid artery stenting CAS 50 receiving PEGINTRON 50 complete cytogenetic response 50 flutamide 50 clopidogrel Plavix 50 baseline Hb 50 lobectomy 50 prospectively evaluated 50 subtrochanteric 50 salmeterol fluticasone propionate 50 severe exacerbations 50 cisplatin vinorelbine 50 Index CDAI score 50 recurrent malignant glioma 50 debulking surgery 50 PASI scores 50 acute STEMI 49 Score TOS 49 oxycodone IR 49 symptomatic intracerebral hemorrhage 49 q#h 49 alfa 2a 49 dosing cohorts 49 highly emetogenic 49 COPAXONE ® 49 Response Evaluation Criteria 49 secondary efficacy endpoint 49 carotid endarterectomy CEA 49 Engerix B 49 URTI 49 systolic dysfunction 49 Unstable Angina 49 bone marrow reticulin deposition 49 receiving SIMPONI 49 elevated LDH 49 candidemia 49 hemodialysis patients 49 CABG 49 aldosterone antagonists 49 TORISEL 49 axillary node dissection 49 unresectable stage 49 DAPT 49 RAPAFLO R 49 primary patency 49 abnormal p# biomarker 49 ug dose 49 Paraplatin ® carboplatin 49 Elitek 49 fondaparinux 49 ribavirin therapy 49 steroid dexamethasone 49 symptomatic VTE 49 candesartan cilexetil 49 NCCTG N# 49 methotrexate monotherapy 49 ritonavir boosted atazanavir 49 revascularization procedures 49 serum phosphate 49 external beam radiotherapy 49 moderate renal impairment 49 cisplatin gemcitabine 49 recurrent ischemia 49 gemcitabine carboplatin 49 plus gemcitabine 49 clinically meaningful improvement 49 refractory ischemia 49 confirmed CCyR 49 Newly Diagnosed Multiple Myeloma 49 TAVR 49 recurrent GBM patients 49 drug eluting stent implantation 49 FluCAM 49 CR nPR 49 Pegasys plus Copegus 49 death reinfarction 49 goserelin 49 DAS# CRP 49 aldosterone antagonist 49 pegylated interferon alfa 2a 49 infusional 49 interferon alfa 2a 49 pancreatic resection 49 mg BID dose 49 Pred Forte 49 myocardial infarction MI 49 treated nonsurgically 49 mycophenolate mofetil 49 DAS# scores 49 intravenous diuretics 49 MIRAPEX 49 metastatic hormone refractory 49 EDSS scores 49 imipenem 49 hepatic metastases 49 BENICAR HCT 49 infliximab monotherapy 49 thrombocytopenic 49 ER CHOP 49 docetaxel prednisone 49 colorectal liver metastases 49 radiofrequency ablation RFA 49 standard chemotherapy regimens 49 metastatic bone 49 KRAS mutant tumors 49 unresectable tumors 49 intravesical therapy 49 histologically confirmed 49 ARCOXIA 49 platinum chromium PROMUS 49 resected pancreatic cancer 49 splenectomized 49 β blockers 49 clinically meaningful improvements 49 ACR# response 49 rosuvastatin #mg 49 adjunctive placebo 49 TURP 49 chemoradiotherapy 49 worsening thrombocytopenia 49 mg QD 49 taxotere 49 CYPHER R Stent 49 ejection fractions 49 oral Hycamtin 49 alfuzosin 49 fluvoxamine Luvox 49 Montgomery Asberg Depression 49 sorafenib Nexavar 49 venlafaxine Effexor 49 abciximab 49 DOXIL ® 49 bivalirudin alone 49 adjuvant radiation 49 hemoglobin A1c levels 49 adalimumab Humira 49 Acute Coronary Syndromes 49 androgen suppression 49 urinary N telopeptide 49 pT3 49 prednisone VcMP 49 HERCEPTIN 49 enoxaparin 49 leucopenia 49 achieved mucosal healing 49 metastatic renal cell carcinoma 49 CLL SLL 49 #mg dose [001] 49 SVR# 49 tapentadol ER 49 sirolimus eluting stents 49 concurrent chemoradiation 49 DOXIL 49 mL/min/#.# m 2 49 salmeterol fluticasone 48 ximelagatran 48 ACE inhibitors beta blockers 48 allogeneic hematopoietic stem cell 48 DES implantation 48 radical nephrectomy 48 Relapsed Refractory Multiple Myeloma 48 dacarbazine DTIC 48 Retreatment 48 relapsing multiple sclerosis 48 unresectable HCC 48 abdominal pain abdominal discomfort 48 atrioventricular block 48 Patency 48 colectomy 48 endarterectomy 48 postoperative morbidity 48 postmenopausal osteoporotic women 48 receiving INTRON 48 gout flares 48 #mg QD [002] 48 IFL chemotherapy regimen 48 care regimens CCR 48 mcg BID 48 adenotonsillectomy 48 STEMI patients 48 daily Infergen 48 melphalan prednisone 48 evaluating REVLIMID 48 ATACAND 48 DAS# [002] 48 composite endpoint 48 serum clusterin levels 48 beam radiotherapy 48 oral clodronate 48 5-fluorouracil/leucovorin 48 paclitaxel carboplatin 48 Androgen Deprivation Therapy 48 intracranial stenosis 48 sirolimus stent 48 pooled comparator 48 fluticasone salmeterol 48 CHOP chemotherapy 48 FIRMAGON 48 TAXOTERE ® 48 liver resection 48 vinorelbine 48 NEVO 48 mg/m2 IV 48 TAXUS Stent 48 prostate cancer CRPC 48 unfractionated heparin 48 symptomatic intracranial 48 posttransplant 48 radical cystectomy 48 docetaxel pretreated 48 dose cohort 48 pain palliation 48 daunorubicin 48 Ishak fibrosis score 48 Fludara 48 FFR guided 48 invasive candidiasis 48 invasive aspergillosis 48 variceal hemorrhage 48 Crohn Disease Activity 48 baseline PASI 48 fludarabine 48 bypass grafting 48 aromatase inhibitor therapy 48 androgen suppression therapy 48 relapsed CLL 48 enalapril 48 percutaneous transluminal coronary angioplasty 48 lumbar spine BMD 48 Metastatic Prostate Cancer 48 elevated troponin 48 undetectable viral 48 multicenter randomized controlled 48 TAXUS IV 48 azacitidine 48 landmark ATHENA trial 48 Betaferon R 48 retrospectively analyzed 48 free survival PFS 48 severe hypoglycemic 48 mCRC acneform rash 48 low dose dexamethasone 48 target lesion revascularization 48 experienced virologic failure 48 Scale EDSS 48 XIENCE V vs. 48 % CI #.#-#.# [007] 48 FOLFOX6 48 FUSILEV enhances 48 annualized relapse 48 FFNS 48 EBRT 48 trastuzumab Herceptin R 48 graft occlusion 48 chronic GVHD 48 mcg Albuferon 48 transfemoral 48 liposome injection 48 advanced hepatocellular carcinoma 48 complete cytogenetic 48 revascularizations 48 #.#/#.# mmHg [001] 48 CDAI 48 empyema 48 MADIT CRT trial 48 pegylated interferon peg IFN 48 Pegasys ® 48 Tumors shrank 48 esophageal candidiasis 48 radical prostatectomy 48 ruboxistaurin 48 colorectal adenoma 48 bortezomib refractory 48 medically inoperable 48 TLUS 48 sirolimus eluting stent 48 UA NSTEMI 48 Pemetrexed 48 intravenous tPA 48 adjuvant radiotherapy 48 esomeprazole 48 mCRPC 48 highly emetogenic chemotherapy 48 Patients Receiving 48 BR.# 48 nonoperative 48 metastatic gastric 48 simvastatin ezetimibe 48 Lucrin 48 febrile neutropenia 48 Cystectomy 48 pravastatin therapy 48 μg dose 48 surgical debulking 48 unfractionated heparin UFH 48 BENICAR 48 stroke myocardial infarction 48 mg qd 48 rimonabant #mg/day 48 FOLFOX6 chemotherapy regimen 48 dual antiplatelet therapy 48 Castration Resistant Prostate Cancer 48 placebo PBO 48 bronchial thermoplasty 48 bicalutamide 48 underwent radical cystectomy 48 treat brain aneurysms 48 dose statin therapy 48 Aromasin 48 Montgomery Åsberg Depression 48 echinacea tablets 48 elective PCI 48 sipuleucel T 48 postoperative radiotherapy 48 #mg/day [002] 48 sustained virological response 48 SUVmax 48 serum urate 48 5FU 48 distant metastasis 48 abacavir lamivudine 48 nonsmall cell lung cancer 48 androgen deprivation 48 ancrod 48 thromboembolic complications 48 relapsed multiple myeloma 48 inflammatory lesions 48 gefitinib Iressa 48 pulmonary exacerbation 48 receiving VELCADE 48 FOLFOX regimen 48 rimonabant #mg 48 carotid endarterectomy 48 severe renal impairment 48 bivalirudin 48 #mg dosing group 48 ABC/3TC 48 nausea somnolence 48 Idiopathic Pulmonary Fibrosis 48 inhaled tobramycin 48 GOUT 48 ABSORB trial 48 daily subcutaneous injections 48 operable breast cancer 48 partial remissions 48 radial artery grafts 48 infarction NSTEMI 48 etanercept 48 LV dysfunction 48 ACR# responses 48 creatinine clearance 47 rFVIIa 47 HBeAg seroconversion 47 prior chemotherapy regimens 47 PEG Intron 47 RECORD1 47 target vessel revascularization 47 Decompensated Heart Failure 47 mg administered orally 47 NovoTTF 47 topotecan 47 repeat revascularization 47 serum phosphate levels 47 RE LY 47 epoetin alpha 47 desvenlafaxine succinate 47 remission CR 47 relapsed Hodgkin lymphoma 47 #mg BID [003] 47 atherosclerotic renal artery stenosis 47 AEGR 47 PREZISTA r 47 stable angina pectoris 47 peginterferon alfa 2a #KD 47 hyperthermia therapy 47 Kaplan Meier analysis 47 postprocedure 47 Instanyl 47 Kaplan Meier estimate 47 IRLS score 47 ipsilateral breast 47 mg RDEA# 47 colorectal cancer liver metastases 47 underwent coronary angiography 47 CNS LS 47 citalopram Celexa 47 coronary revascularization 47 tolterodine 47 coronary intervention 47 ALA PDT 47 cytogenetic responses 47 Alkeran 47 coronary artery bypass grafts 47 virologic response 47 lobular cancer 47 Warach 47 locoregional control 47 dosage regimens 47 heavily pretreated 47 prostate cancer HRPC 47 kyphoplasty procedures 47 evaluating tivozanib 47 TAXUS Liberte Long 47 neoadjuvant radiation 47 VaD 47 AVONEX ® 47 Secondary endpoints 47 #mg doses [002] 47 voriconazole 47 upper gastrointestinal bleeding 47 onset atrial fibrillation 47 evaluable 47 GLIADEL R Wafer 47 Abciximab 47 Venous thromboembolism 47 measurable tumor regressions 47 Taxotere ® 47 plus prednisone prednisolone 47 glycoprotein IIb IIIa inhibitors 47 5 FU leucovorin 47 dapagliflozin plus 47 autoantibody positive 47 estramustine 47 tolterodine ER 47 SLND alone 47 docetaxel Taxotere ® 47 paricalcitol 47 TAXUS p value 47 Subgroup analysis 47 mg Proellex 47 Carotid Revascularization Endarterectomy vs. 47 achieved CCyR 47 Thrombolysis 47 cisplatin chemotherapy 47 Neoadjuvant 47 dabigatran etexilate 47 pyridostigmine 47 myocardial infarctions 47 #.#mg/dL 47 Cladribine tablets 47 rt PA 47 Paraplatin ® 47 induce remission 47 thalidomide Thalomid 47 TAXOTERE R 47 antithrombotic therapy 47 Sirolimus eluting Coronary Stent 47 NMIBC 47 thrombolytic agents 47 lopinavir r 47 telaprevir dosed 47 mg TID 47 fluvastatin 47 peginterferon 47 Follicular Lymphoma 47 carotid stenosis 47 hormone refractory metastatic prostate 47 NSTEMI 47 cilostazol 47 abatacept Orencia 47 nonfatal MI 47 GPIIb IIIa inhibitors 47 macrolide antibiotic 47 cabazitaxel 47 ethambutol 47 Solid Tumors 47 Renal Cell Carcinoma RCC 47 peripheral arterial occlusive disease 47 pegylated liposomal doxorubicin PLD 47 moderate hepatic impairment 47 prednisone prednisolone plus 47 splenectomized patients 47 LEXIVA r 47 idarubicin 47 platinum refractory 47 System USRDS 47 pulmonary resection 47 nonvertebral fractures 47 adenoma recurrence 47 underwent radical prostatectomy 47 EURIDIS 47 APTIVUS R 47 #mg ATC 47 Dialysis Outcomes 47 PREZISTA r arm 47 tamoxifen therapy 47 hepatitis C genotype 47 Mitomycin C 47 UPDRS motor 47 PERSEUS clinical program 47 TEAEs 47 severe aortic stenosis 47 severe mitral regurgitation 47 radiotherapy RT 47 chronic periodontitis 47 preserved ejection fraction 47 GERD symptom 47 unresectable 47 Stent thrombosis 47 null responders 47 Taxotere R 47 postsurgical pain 47 tiotropium 47 pomalidomide 47 gastrointestinal perforation 47 placebo 47 ischemic stroke 47 cladribine tablets 47 HbA 1c levels 47 undergoing peritoneal dialysis 47 paclitaxel Taxol ® 47 Torisel 47 MMSE scores 47 refractory multiple myeloma 47 Renal Insufficiency 47 stent implantation 47 tamoxifen Nolvadex ® 47 secondary endpoint 47 CMV disease 47 low dose cytarabine 47 metastatic malignant 47 azathioprine 47 ARIMIDEX 47 symptomatic aortic stenosis 47 Fulvestrant 47 dexamethasone Decadron 47 macular edema secondary 47 captopril 47 serum sodium levels 47 relapsed SCLC 47 metastatic RCC 47 recurrent NSCLC 47 refractory AML 47 antiplatelet medication 47 postherpetic neuralgia PHN 47 antiretroviral naïve 47 postoperative complication 47 mitomycin 47 oral deforolimus 47 FROVA 47 acutely decompensated heart 47 pantoprazole 47 interferon alfa 47 fibrinolysis 47 ST Elevation Myocardial 47 cetuximab Erbitux R 47 antiretroviral naive 47 efavirenz EFV 47 CHARM Added 47 Platinol 47 carotid stents 47 hypofractionated radiation 47 Irinotecan 47 mg/m2/day 47 chemotherapy regimen 47 intracerebral hemorrhage 47 invasive carcinomas 47 NYHA functional class 47 RE LY ® 47 relapsing remitting MS RRMS 47 APTIVUS r 47 #mg q8h 47 unstable angina pectoris 47 RECIST Response Evaluation Criteria 47 Selective Internal 47 ST elevation myocardial 47 sevelamer 47 Doxil 47 esophagectomy 47 glycated hemoglobin HbA1c 47 RSD# oral 47 XIENCE V PROMUS Stent 47 AZT zidovudine Retrovir 47 infarction STEMI 47 Virologic 47 bevacizumab Avastin ® 47 dexmedetomidine 47 levofloxacin 47 CIMZIA R 47 Metastatic Breast Cancer 47 pancreatic carcinoma 47 CABG surgery 47 folinic acid 47 breastfed exclusively 47 NAVISTAR R 47 oral leukoplakia 47 alteplase 47 GnRH agonist 47 WBRT 47 p = #.# [003] 47 biliary tract cancer 47 Femara letrozole 47 stent DES 47 CRT ICD 47 Platelet Inhibition 47 chlorthalidone 47 CDAI score 47 atherothrombotic events 47 achieved statistical significance 47 median survivals 47 total abdominal hysterectomy 47 tapentadol IR 47 #Gy 47 Soft Tissue Sarcoma 47 Dermatologic toxicities 47 anthracyclines taxanes 47 Previously Untreated 47 Neulasta R 47 colorectal metastases 47 doxazosin 47 postsurgical 47 TYSABRI therapy 47 metastatic lung cancer 46 EXJADE 46 Zyclara 46 intravenous vancomycin 46 PEG IFN 46 mg ustekinumab 46 IOP lowering 46 GG genotype 46 pneumonectomy 46 HBeAg negative 46 specific antigen PSA 46 infarct size 46 mg/m2 46 pregabalin 46 #mg/m# [001] 46 HIV HCV coinfected 46 metastatic renal cell 46 undetectable HCV RNA 46 paclitaxel Taxol R 46 -#.# log# 46 neutrophil counts 46 discontinuations due 46 gemcitabine Gemzar 46 AGILECT R 46 TAXUS ® 46 LVSD 46 retinal thickness 46 receiving Vectibix monotherapy 46 sertraline Zoloft 46 infliximab Remicade 46 patients evaluable 46 candesartan 46 Xelox 46 thrombolytics 46 Paroxysmal Nocturnal Hemoglobinuria PNH 46 angiographic restenosis 46 echocardiographic parameters 46 ORAL HYCAMTIN 46 Camptosar ® 46 WBRT alone 46 thiazide diuretic 46 Hycamtin ® 46 ischemia driven 46 undetectable PSA 46 cytopenias 46 hepatocellular carcinomas 46 CIPN 46 sunitinib Sutent 46 DMARD therapy 46 crossclamp 46 aged ≥ 46 Index CDAI 46 sorafenib tablets 46 normothermic 46 mild renal insufficiency 46 bowel resection 46 lenalidomide Revlimid R 46 EVIZON 46 CIMZIA ™ 46 Carotid artery stenting 46 neutropaenia 46 prospective nonrandomized 46 benazepril 46 ceftazidime 46 Serious adverse reactions 46 pancreatic adenocarcinoma 46 nonfatal myocardial infarction 46 pT2 46 alanine aminotransferase ALT 46 ketorolac 46 hypophosphatemia 46 weekly intravenous infusions 46 antiarrhythmic drug 46 MYCAMINE 46 doxorubicin HCl liposome injection 46 Nesiritide 46 thrombotic events 46 NovoTTF #A 46 de novo AML 46 elevated transaminases 46 oral vancomycin 46 VT VF 46 oral antidiabetic medication 46 metastatic carcinoid 46 invasive ductal 46 induce orthostatic hypotension 46 reintervention 46 undergoing coronary angiography 46 lymph node involvement 46 recurrent glioblastoma 46 chemo radiotherapy 46 LUCENTIS 46 CRESTOR #mg 46 DMARDs 46 dosing cohort 46 Cypher Stent 46 lung metastases 46 Patients Treated 46 axillary lymph node dissection